A 24-week randomized trial in 249 Indian adults with obesity found that generic semaglutide produced virtually identical weight loss to brand-name Wegovy: 14.39% versus 14.61% body weight reduction. Both formulations achieved the critical 10% weight loss threshold in over 83% of participants, with similar safety profiles and adverse event rates around 55%. This represents the first major non-inferiority study demonstrating that biosimilar GLP-1 receptor agonists can deliver outcomes indistinguishable from innovator products. The finding carries profound implications for global obesity treatment accessibility, particularly in cost-sensitive markets where branded semaglutide remains prohibitively expensive. With obesity rates climbing worldwide and healthcare systems strained, validated generic alternatives could democratize access to this transformative weight management intervention. However, the study's limitation to a single ethnic population over six months leaves questions about long-term efficacy and cross-population generalizability. The 98.8% completion rate suggests excellent tolerability, but extended safety data remains crucial given semaglutide's recent market concerns. This confirmatory evidence positions generic semaglutide as a viable pathway to expand obesity treatment reach globally.